These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 15952984

  • 1. Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester.
    Christiansen M, Nørgaard-Pedersen B.
    Clin Genet; 2005 Jul; 68(1):35-9. PubMed ID: 15952984
    [Abstract] [Full Text] [Related]

  • 2. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, Groome NP, Macri JN, Connor JM.
    N Engl J Med; 1996 May 09; 334(19):1231-6. PubMed ID: 8606718
    [Abstract] [Full Text] [Related]

  • 3. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME, First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium.
    Obstet Gynecol; 2006 Nov 09; 108(5):1192-9. PubMed ID: 17077242
    [Abstract] [Full Text] [Related]

  • 4. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
    Spencer K.
    Ann Clin Biochem; 2005 Jan 09; 42(Pt 1):30-40. PubMed ID: 15802030
    [Abstract] [Full Text] [Related]

  • 5. First-trimester or second-trimester screening, or both, for Down's syndrome.
    Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME, First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium.
    N Engl J Med; 2005 Nov 10; 353(19):2001-11. PubMed ID: 16282175
    [Abstract] [Full Text] [Related]

  • 6. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS, Nasrat HA, Rouzi AA, Qari MH, Al-Qahtani MH, Abuzenadah AM.
    Prenat Diagn; 2007 Apr 10; 27(4):303-11. PubMed ID: 17269128
    [Abstract] [Full Text] [Related]

  • 7. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Feb 10; 27(2):151-5. PubMed ID: 16388509
    [Abstract] [Full Text] [Related]

  • 8. Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester.
    Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH.
    Prenat Diagn; 2001 Jun 10; 21(6):441-4. PubMed ID: 11438945
    [Abstract] [Full Text] [Related]

  • 9. Prenatal screening for Down's syndrome using inhibin-A as a serum marker.
    Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG.
    Prenat Diagn; 1996 Feb 10; 16(2):143-53. PubMed ID: 8650125
    [Abstract] [Full Text] [Related]

  • 10. Increased time-to-pregnancy and first trimester Down's syndrome screening.
    Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S.
    Hum Reprod; 2010 Feb 10; 25(2):412-7. PubMed ID: 19945962
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A, Grunewald C, Saltvedt S, Valentin L, Almström H.
    Acta Obstet Gynecol Scand; 2006 Feb 10; 85(5):534-8. PubMed ID: 16752230
    [Abstract] [Full Text] [Related]

  • 13. Second-trimester dimeric inhibin-A in Down's syndrome screening.
    Spencer K, Wallace EM, Ritoe S.
    Prenat Diagn; 1996 Dec 10; 16(12):1101-10. PubMed ID: 8994245
    [Abstract] [Full Text] [Related]

  • 14. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome.
    Cuckle HS, Holding S, Jones R, Groome NP, Wallace EM.
    Prenat Diagn; 1996 Dec 10; 16(12):1095-100. PubMed ID: 8994244
    [Abstract] [Full Text] [Related]

  • 15. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K, Bindra R, Cacho AM, Nicolaides KH.
    Prenat Diagn; 2004 Mar 10; 24(3):169-73. PubMed ID: 15057947
    [Abstract] [Full Text] [Related]

  • 16. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME, First and Second Trimester Evaluation of Risk (FASTER) Research Consortium.
    Obstet Gynecol; 2007 Sep 10; 110(3):651-7. PubMed ID: 17766613
    [Abstract] [Full Text] [Related]

  • 17. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Sep 10; 32(4):488-92. PubMed ID: 18726925
    [Abstract] [Full Text] [Related]

  • 18. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
    Bestwick JP, Huttly WJ, Wald NJ.
    J Med Screen; 2008 Sep 10; 15(4):204-6. PubMed ID: 19106261
    [Abstract] [Full Text] [Related]

  • 19. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
    Ultrasound Obstet Gynecol; 2005 Mar 10; 25(3):221-6. PubMed ID: 15736186
    [Abstract] [Full Text] [Related]

  • 20. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 May 10; 31(5):493-502. PubMed ID: 18432600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.